PL2148681T3 - Selektywny modulator progesteronu w leczeniu krwawienia z macicy - Google Patents

Selektywny modulator progesteronu w leczeniu krwawienia z macicy

Info

Publication number
PL2148681T3
PL2148681T3 PL08737471.6T PL08737471T PL2148681T3 PL 2148681 T3 PL2148681 T3 PL 2148681T3 PL 08737471 T PL08737471 T PL 08737471T PL 2148681 T3 PL2148681 T3 PL 2148681T3
Authority
PL
Poland
Prior art keywords
modulators
treatment
uterine bleeding
selective progesterone
progesterone
Prior art date
Application number
PL08737471.6T
Other languages
English (en)
Inventor
Bartholomeus C. J. M. Fauser
Ernest Loumaye
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2148681T3 publication Critical patent/PL2148681T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08737471.6T 2007-04-20 2008-04-18 Selektywny modulator progesteronu w leczeniu krwawienia z macicy PL2148681T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90787507P 2007-04-20 2007-04-20

Publications (1)

Publication Number Publication Date
PL2148681T3 true PL2148681T3 (pl) 2016-09-30

Family

ID=39766931

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08737471.6T PL2148681T3 (pl) 2007-04-20 2008-04-18 Selektywny modulator progesteronu w leczeniu krwawienia z macicy

Country Status (13)

Country Link
US (2) US8569274B2 (pl)
EP (1) EP2148681B1 (pl)
JP (2) JP5785392B2 (pl)
CA (1) CA2684450C (pl)
CY (1) CY1117586T1 (pl)
DK (1) DK2148681T3 (pl)
ES (1) ES2575554T3 (pl)
HR (1) HRP20160689T1 (pl)
HU (1) HUE029397T2 (pl)
PL (1) PL2148681T3 (pl)
PT (1) PT2148681E (pl)
SI (1) SI2148681T1 (pl)
WO (1) WO2008129396A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TW201002736A (en) * 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
CN102906103A (zh) * 2010-03-22 2013-01-30 利普生物药剂公司 用于抗孕酮的非毒性递送的组合物和方法
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP2015509538A (ja) * 2012-03-07 2015-03-30 リガンド・ファーマシューティカルズ・インコーポレイテッド １つに統合された恒常性システムとしてのステロイドホルモン経路およびコレステロール経路
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
SG11201407397WA (en) 2012-05-31 2014-12-30 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
JP6343619B2 (ja) 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
US20150320766A1 (en) * 2012-12-14 2015-11-12 Laboratoire Hra-Pharma Copper intrauterine device
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP6995757B2 (ja) 2015-12-23 2022-01-17 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
US11124537B2 (en) 2015-12-23 2021-09-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
PT3523315T (pt) 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
ES2196063T3 (es) 1995-02-02 2003-12-16 Schering Ag Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
ES2152671T3 (es) * 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
JP5017109B2 (ja) * 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
PL1809602T3 (pl) * 2004-10-27 2009-04-30 Janssen Pharmaceutica Nv Pochodne indolowe przydatne jako modulatory receptora progesteronu

Also Published As

Publication number Publication date
PT2148681E (pt) 2016-06-17
JP5804654B2 (ja) 2015-11-04
US8569274B2 (en) 2013-10-29
WO2008129396A3 (en) 2009-08-13
CA2684450C (en) 2017-05-30
SI2148681T1 (sl) 2016-07-29
CA2684450A1 (en) 2008-10-30
DK2148681T3 (en) 2016-07-04
HUE029397T2 (en) 2017-03-28
WO2008129396A2 (en) 2008-10-30
HRP20160689T1 (hr) 2016-07-15
JP2010524915A (ja) 2010-07-22
EP2148681A2 (en) 2010-02-03
JP2013253098A (ja) 2013-12-19
US20140100208A1 (en) 2014-04-10
EP2148681B1 (en) 2016-03-16
US20150051180A9 (en) 2015-02-19
US20100190758A1 (en) 2010-07-29
CY1117586T1 (el) 2017-04-26
JP5785392B2 (ja) 2015-09-30
ES2575554T3 (es) 2016-06-29

Similar Documents

Publication Publication Date Title
HRP20160689T1 (hr) Selektivni modulatori progesterona za tretman uterinog krvarenja
HK1223025A1 (zh) 組織閉塞劑
PT2337568T (pt) Processos e métodos para engenharia de tecidos moles
ZA201204267B (en) Nestorone/ estradiol transdermal gel
EP2146643A4 (en) SURGICAL RETRACTOR WITH PADDED
EP2124958A4 (en) TREATMENT OF IL DR SYNDROME BY EMPLOYING TESTOSTERONE AND PROGESTAGEN
HK1136975A1 (zh) 用於防止早產的孕酮
SG10201408158SA (en) Composition and methods used during anti-hiv treatment
EP2187957A4 (en) SELECTIVE CYTOPHERESIS DEVICES AND CORRESPONDING METHODS
GB0603481D0 (en) Slow release agent absorbent dressing
EP2250978A4 (en) CERVICAL MASSAGE DEVICE
EP2114377A4 (en) CONTROLLED RELEASE OF ACTIVE SUBSTANCES IN THE SKIN
HRP20181728T1 (hr) Postupci liječenja analne inkontinencije mioblastima
GB0714440D0 (en) Rupturing device
EP2517007A4 (en) METHOD AND KITS FOR IDENTIFYING SEROTYPES OF HUMAN ADENOVIRES
GB0816650D0 (en) Therapeutic bone grwth and regeneration
EP2249849A4 (en) COMBINATION THERAPY WITH ACTINIDIA AND STEROIDS AND USES THEREOF
GB0606921D0 (en) Skin dressing
EP2375994A4 (en) STYPTIC DEVICE
EP2327407A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR FUNCTIONAL DISORDERS OF THE DIGESTIVE TUBE
EP2140876A4 (en) THERAPEUTIC AGENT COMPRISING VASOHIBINE
ZA200904913B (en) Use of VEGF in the treatment of retarded fetal growth in pregnancy
GB2438373B (en) Uterine dilators set
GB2450368B (en) Hemorrhoid treatment device
EP2285328A4 (en) DEVICE FOR TREATING HEMORRHOIDS